Use of Insoluble Dietary Fiber and Probiotics for Bowel Preparation Before Colonoscopy: A Prospective Study

Kensuke Kudou, MD, PhD,*† Koich Kimura, MD, PhD,* Ryosuke Tsutsumi, MD, PhD,* Naotaka Hashimoto, MD, PhD,* Hiroya Wada, MD, PhD,* and Tetsuo Ikeda, MD, PhD*†

Background: In screening colonoscopy, patients usually have to ingest large amounts of bowel-cleansing agents, including polyethylene glycol (PEG). This is difficult and has various side effects; thus, patients avoid undergoing a colonoscopy. We tested a novel bowel preparation method before colonoscopy using insoluble dietary fiber and probiotics (PB).

Methods: This was a prospective clinical study conducted between October 2018 and March 2019 at a general hospital. Forty participants were randomly assigned to low-volume PEG solution diet (MoviPrep), wheat bran fiber (WBF) and probiotic *Bifidobacterium animalis* subsp. *lactis* GCL2505 (PB GCL2505), or standard-volume regimen (1.0 to 1.5 L of MoviPrep) (control group). The patient compliance and the quality of bowel preparation were evaluated.

Results: Forty individuals aged 38 to 83 years were randomly assigned to the WBF with PB (n = 20) and control (n = 20) groups. All participants underwent bowel preparation before colonoscopy according to each protocol. The mean required volume of MoviPrep was significantly lower in the WBF with PB group than in the control group (582.5 vs. 1305 mL, *P* < 0.0001). Successful bowel-cleansing rates were not significantly different between the 2 groups; however, the ratio of the Harefield Cleansing Scale grades C and D was significantly lower in the WBF with PB group than in the control group (*P* = 0.0471).

Conclusions: The intake of WBF and GCL2505 before colonoscopy reduces the required PEG quantities while maintaining bowel-cleansing quality. This novel, minimally invasive pre-treatment method makes colonoscopy more accessible contributing to the prevention and early treatment of colorectal cancer.

Key Words: colonoscopy, dietary fiber, probiotics, bowel preparation, cancer screening

†Received for publication May 6, 2021; accepted June 18, 2021.

From the *Department of Endoscopy and Endoscopic Surgery, Oral Medicine Research Center, Fukuoka Dental College Medical and Dental Hospital; †Department of Gastroenterology Surgery, Clinical Research Institute Cancer Research Division, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

The authors declare no conflicts of interest.

Reprints: Tetsuo Ikeda, MD, PhD, Department of Endoscopy and Endoscopic Surgery, Oral Medicine Research Center, Fukuoka Dental College Medical and Dental Hospital, 2-15-1 Tamura, Sawara-ku, Fukuoka 814-0193, Japan (e-mail: ikeda@college.fcnet.ac.jp).

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and build upon the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

To ensure high-quality screening colonoscopy, adequate bowel-cleansing is essential. In recent years, the morbidity and mortality rates of colorectal cancer have been increasing globally.1 Currently, colonoscopy is the most effective method in preventing the occurrence of colorectal cancer or detecting colorectal cancer at an early stage so that superficial cancers can be resected.2 Nevertheless, participation rates for colonoscopy are unsatisfactory. For example, participation rates range from 20% to 39% in most countries.3 ⁵ One of the major reasons the patients avoid undergoing colonoscopy is the need to ingest large amounts of bowel-cleansing agents, including polyethylene glycol (PEG) for bowel preparation, which may cause various side effects, such as nausea and hypotension, dehydration, and intestinal obstruction. Furthermore, forced irrigation of the intestinal tract with a large amount of intestinal lavage may adversely affect the intestinal flora.

To resolve these challenges, we developed a novel method that reduces the dose of bowel-cleansing agents and promotes bowel movements by ingesting foods that promote natural defecation, instead of forced cleansing with intestinal flush, as in the conventional method. Briefly, we focused on 2 dietary factors, namely, insoluble dietary fiber [wheat bran fiber (WBF)] and probiotics (PB; *Bifidobacterium animalis* subsp. *lactis* GCL2505).3 ⁵ A recent study reported that the daily intake of > 20 g of wheat bran cereal significantly increased stool volume and its intake of 20 to 50 g/d would be effective in improving constipation. Ishizuka et al7 reported an increase in the defecation frequency with GCL2505 administration than with placebo. Takii et al8 reported that the defecation frequency and stool quantity increased significantly with consumption of GCL2505 fermented milk compared with that with placebo. These results suggested that GCL2505 improved constipation by increasing intestinal bifidobacteria.

On the basis of these studies, we hypothesized that WBF and GCL2505 would support bowel-cleansing while reducing adverse effects on the intestinal flora. Thus, this study aimed to investigate the safety and efficacy of ingesting wheat bran cereal and GCL2505 as a novel method for bowel preparation before screening colonoscopy.

METHODS

Study Participants

This prospective clinical study was conducted between October 2018 and March 2019 at a general hospital. The inclusion criteria were as follows: scheduled colonoscopy and provision of informed consent for examination, ability to achieve ordinary oral intake, full understanding of the study design and provision of informed consent, and age 20 years and above at the time of acquiring consent. In contrast, the exclusion criteria were as follows: obstruction of the gastrointestinal tract,
poor general conditions (performance status score ≥ 3), and
judged by the investigators as inappropriate for this study.
Written informed consent was obtained from all patients in
accordance with the respective institutional regulations, and the
study protocol was approved by the ethics committee of
Fukuoka Medical and Dental College Hospital (registration
number, 420; approval date, September 3, 2018).

The study participants were randomly categorized into
2 groups. Participants in 1 group received the novel regimen
for bowel preparation using WBF and PB GCL2505 (WBF
with PB group), and the remaining participants received the
standard-volume regimen (1.0 to 1.5 L of PEG solution)
(control group). The 40 eligible participants were randomly
assigned in a 1:1 ratio to these groups, and data from par-
ticipants in each group were analyzed.

Study Procedures

The degree of constipation in individuals in the WBF with
PB group was assessed using the Bristol Stool Form Scale
(BSFS) and Constipation Scoring System (CSS). Participants
with a BSFS score ≤ 2 or CSS score ≥ 1 were classified
into the constipation group, and the remaining participants with
a BSFS score ≥ 3 and CSS score < 1 were classified into the
nonconstipation group. In the nonconstipation group, particip-
ants had regular meals until 2 days before the colonoscopy.
On the day before the colonoscopy, only WBF and PB meals
were allowed. As per the protocol, consuming at least 3 meals of
40 g of WBF (Kellogg All Bran) and 125 g of PB (Glico BifiX
yogurt) per meal was recommended. Participants in the con-
stitution group had a meal of 40 g of WBF and 125 g of PB
from 4 to 2 days before the colonoscopy, in addition to the
regular meals. On the day before the colonoscopy, only WBF
and PB were permitted as meals, as in the nonconstipation
group. On the day of the colonoscopy, participants in the WBF
with PB group were prepared with oral intake of 0.5 L of PEG
solution (Moviprep; PEG, sodium sulfate, sodium chloride,
potassium chloride, sodium ascorbate, and ascorbic acid). In the
control group, the standard-volume regimen (1.0 to 1.5 L of
Moviprep) was administered (Fig. 1). When the proper con-
tion of stool was not satisfied, additional preparation was
conducted by having patients ingest Moviprep.

Patient compliance and the quality of bowel preparation
were compared between the 2 groups. The quality of bowel
preparation was evaluated using the Harefield Cleansing Scale. Endoscopic findings identified as Harefield
Cleansing Scale grade A [all segments scored 3 (clear liquid)
or 4 (empty and clean)] or grade B [1 or more segments
scored 2 (brown liquid/removable semisolid stools)] were
regarded as successful bowel preparations (Fig. 2).

The primary outcome in the present study was a com-
parison of the quality of bowel preparation between the 2
groups, whereas the secondary outcome was a comparison of
the actual required volume of Moviprep between the 2 groups.

Statistical Analysis

Differences in characteristics between the groups were
evaluated using Fisher exact tests or unpaired t tests. All P
values were 2-sided, and a P-value of < 0.05 was considered
to reflect statistical significance. All analyses were per-
formed with JMP PRO 13 software (SAS Institute Inc., Cary, NC).

RESULTS

Clinical Features

Forty individuals aged 38 to 83 years were randomly
assigned to the WBF with PB group (n = 20) and control
(group (n = 20). Participants in each group underwent bowel
preparation in accordance with the protocol, followed by
colonoscopy. The baseline characteristics of the 2 groups are
listed in Table 1. No differences were found in sex pro-
portions, presence of constipation, smoking habits, and
alcohol consumption between the groups. The mean age was
significantly higher in the WBF with PB group than in the
control group.

FIGURE 1. Study protocols of bowel preparation in the WBF with PB and control groups. BSFS indicates Bristol Stool Form Scale; CSS,
Constipation Scoring System; PB, probiotics; WBF, wheat bran fiber.
The mean required volume of MoviPrep was significantly lower in the WBF with PB group than in the control group (582.5 vs. 1305 mL, \( P < 0.0001 \)) (Fig. 3). Patient compliance with WBF with PB and MoviPrep in each group is shown in Table 2. No adverse events related to the intake of WBF with PB or MoviPrep were recorded in either group.

The mean intervals between the time of taking MoviPrep and the start time of colonoscopy were 246 minutes (range: 120 to 420 min) in the WBF with PB group and 220 minutes (range: 115 to 305 min) in the control group. There were no significant between-group differences in the mean intervals (\( P = 0.2810 \)). Alternatively, the mean time for the consumption of MoviPrep was 54 minutes (range: 15 to 220 min) in the WBF with PB group which was significantly shorter than the time for the control group (mean, 90 min; range: 25 to 155 min, \( P = 0.0373 \)).

### Colonicoscopy Procedures and Quality of Bowel Preparation

The purpose of colonoscopy was screening for 38 of 40 participants and polypectomy for previously diagnosed polyps and a diagnosis for refractory abdominal pain for the remaining 2 patients. For all the participants in both groups, cecal intubation was accomplished, and screening of all segments was possible. The Harefield Cleansing Scale grades of participants in each group are summarized in Table 3. Successful bowel-cleansing rate was significantly higher in the WBF with PB group (100%) than in the control group (75%) (\( P = 0.0471 \)) (Table 3). The colonoscopy findings from each group are shown in Figure 4. Only powdery residues were noted in the colonoscopy findings of some participants in the WBF with PB group and most of these were easily removable.

Outcomes of colonoscopy in each group are summarized in Table 4. There were no significant between-group differences in the number of detected lesions. Regarding the location of polyps, the proportion of polyps detected in the right side of colon (cecum, ascending colon, and transverse colon) in the WBF with PB group was significantly higher than that of the control group (\( P = 0.0220 \)).

### DISCUSSION

In the present study, we investigated the safety and efficacy of a novel method of bowel preparation by providing patients WBF and GCL2505 before their colonoscopy. We observed reduced requirement of bowel-cleansing agents in the WBF with PB group than in the control group. In addition, the success rates for bowel-cleansing were higher in the WBF with PB rendering this method safe and effective.

---

**TABLE 1. Baseline Demographic and Clinical Features of the WBF+PB and Control Groups**

| Factors          | WBF+PB Group (n = 20) | Control Group (n = 20) | \( P \) |
|------------------|-----------------------|------------------------|-------|
| Sex              |                       |                        |       |
| Male             | 8 (40.0)              | 8 (40.0)               | 1.000 |
| Female           | 12 (60.0)             | 12 (60.0)              |       |
| Age (mean [range]) (y) | 71.8 ± 1.7 (50-82)   | 63.6 ± 3.3 (38-83)     | 0.0339 |
| Constipation     |                       |                        |       |
| No               | 13 (65.0)             | 11 (55.0)              | 0.7475|
| Yes              | 7 (35.0)              | 9 (45.0)               |       |
| Use of laxatives |                       |                        |       |
| No               | 16 (80.0)             | 14 (70.0)              | 0.7164|
| Yes              | 4 (20.0)              | 6 (30.0)               |       |
| Smoking          |                       |                        |       |
| No               | 19 (95.0)             | 20 (100.0)             | 1.0000|
| Yes              | 1 (5.0)               | 0 (0.0)                |       |
| Alcohol consumption |                   |                        |       |
| No               | 15 (75.0)             | 14 (70.0)              | 1.0000|
| Yes              | 5 (25.0)              | 6 (30.0)               |       |

Data are presented as the number (%) unless otherwise stated. PB indicates probiotics; WBF, wheat bran fiber.
We focused on the effect of WBF and GCL2505 on defecation. First, WBF contains large amounts of dietary fiber. The reported effects of dietary fiber include shortened transit time of food in the gastrointestinal tract, increased fecal volume, and reduced blood sugar and cholesterol levels. Dietary fiber is classified as water-soluble dietary fiber and insoluble dietary fiber. The former produces short-chain fatty acids by fermentation of the colon and promotes peristalsis of the intestinal tract, whereas the latter has water-holding properties, softens stool, and increases stool volume by increasing the water content of stools. Among various dietary fibers, cereal fiber is the most beneficial in improving defecation habits. WBF contains abundant insoluble dietary fibers and helps increase the stool volume and frequency, shorten the intestinal transit time, and ensure appropriate stool firmness.

Recommendations for dietary fiber intake in adults range from 20 to 35 g/d. Despite numerous fiber consumption recommendations, the normal intake of dietary fiber is lower than the recommended levels, averaging only 14 to 15 g/d. Generally, the recommended treatment for constipation is the intake of a concentrated source of insoluble fiber, whereas cholesterol levels can be reduced with soluble fiber. In one study, male golden hamsters were fed diets supplemented with 5% cellulose or various amounts of water-insoluble fiber-rich fraction (WIFF; 2.5%, 5%, or 10%). The activities of fecal bacterial enzymes, short-chain fatty acid concentrations, and microbial counts in the cecal content, as well as cecal and fecal biochemical indicators, were evaluated in all hamster groups. Supplementing the diet with WIFF at 2.5% level reduced the hamsters’ daily fecal ammonia production and gastrointestinal transit times. It reduced the activity of β-D-glucosidase, β-D-glucuronidase, mucinase, and urease in feces. Moreover, it elevated the total amount of short-chain fatty acids in the cecal content and promoted the growth of gut microbiota including *Lactobacillus* and *Bifidobacterium*. These results suggested that WIFF improved hamster cecal ecosystem function by reducing toxic compounds excreted by the gut flora.

*Bifidobacteria* have important functions such as suppressing the growth of harmful bacteria, maintaining intestinal flora, regulating the immune system, and suppressing allergies or carcinogenesis. Such physiological effects on the host are brought about by increasing the amounts of *Bifidobacteria* in the intestine. A study reported that continuous intake of a specific strain of *Bifidobacteria* improves the balance of the intestinal flora and fecal properties. Moreover, recent studies have demonstrated that *Bifidobacterium* GCL2505 increased the frequency and amount of defecations and relieved difficulties in defecating.

Increased levels of GCL2505 in the intestine produce short-chain fatty acids such as acetic acid or lactic acid that suppress the growth of harmful bacteria and the production of putrefaction. In addition, short-chain fatty acids regulate intestinal epithelial cells and activate peristaltic movement, and these mechanisms promote defecation. Our method is novel in that it promotes defecation by increasing the amount of stool as a consequence of the effects of WBF and GCL2505 rather than just reducing residue before a colonoscopy. Compared with the conventional preparation method, it is expected that our novel method will have less influence on the environment of the intestinal flora. Furthermore, only powdery residues were observed in participants in the WBF with PB group according to the colonoscopy findings, and these residues were easily removable. These points may be strengths of our method; nevertheless, further investigation is necessary to confirm the validity and utility of this approach.

### TABLE 2. Patient Compliance for Each Bowel Preparation

| Factors          | WBF+PB Group (n = 20) | Control Group (n = 20) | P    |
|------------------|-----------------------|------------------------|------|
| WBF+PB meals     |                       |                        |      |
| Good             | 8 (40.0)              | 8 (40.0)               |      |
| A little hard    | 6 (30.0)              | 6 (30.0)               |      |
| Hard             | 6 (30.0)              | 6 (30.0)               |      |
| Failure          | 0 (0.0)               | 0 (0.0)                |      |
| MoviPrep         |                       |                        |      |
| Good             | 15 (75.0)             | 11 (55.0)              | 0.3203 |
| A little hard    | 4 (20.0)              | 6 (30.0)               |      |
| Hard             | 1 (5.0)               | 3 (15.0)               |      |
| Failure          | 0 (0.0)               | 0 (0.0)                |      |

Data are presented as the number (%). PB indicates probiotics; WBF, wheat bran fiber.

### TABLE 3. Harefield Cleansing Scale Grades of Participants in the WBF With PB and Control Groups

| Harefield Cleansing Scale Grade | WBF With PB Group (n = 20) | Control Group (n = 20) | P    |
|--------------------------------|-----------------------------|------------------------|------|
| A                              | 12 (60.0)                   | 12 (60.0)              |      |
| B                              | 8 (40.0)                    | 3 (15.0)               |      |
| C                              | 0 (0.0)                     | 5 (25.0)               |      |
| D                              | 0 (0.0)                     | 0 (0.0)                |      |
| Success (A-B)                  | 20 (100.0)                  | 15 (75.0)              | 0.0471|
| Failure (C-D)                  | 0 (0.0)                     | 5 (25.0)               |      |

Data are presented as the number (%). PB indicates probiotics; WBF, wheat bran fiber.
A limitation of this study was that it had a small sample size and was a single-institution study. We performed bowel-cleansing with WBF+PB experimentally before the formal design of this study, and the safety and efficacy of this method were empirically confirmed. Therefore, the actual number of cases collected was larger; however, when the study protocol was planned, the minimum number of cases required to prove efficacy was determined so as to allow for the earliest possible publication of our findings. Since the efficacy was proven with a sample of 20 participants, the present study was discontinued, and all subsequent cases in our hospital are currently receiving the WBF+PB protocol.

Although further accumulation of cases is desirable, we believe that the safety and efficacy of the new method have been demonstrated through this study.

In conclusion, the intake of WBF and GCL2505 before colonoscopy can reduce the required quantities of PEG while maintaining the bowel-cleansing quality. This minimally invasive pretreatment method makes colonoscopy more accessible and is expected to contribute to the prevention and early treatment of colorectal cancer.

ACKNOWLEDGMENT

The authors thank Editage (www.editage.jp/) for editing a draft of this manuscript.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687–696.
3. Bretthauer M, Kaminski MF, Løberg M, et al. Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial. JAMA Intern Med. 2016;176:894–902.
4. Stoop EM, de Haan MC, de Wijkerslooth TR, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomized controlled trial. Lancet Oncol. 2012;13:55–64.
5. Salas D, Vanaclocha M, Ibáñez J, et al. Participation and detection rates by age and sex for colonoscopy versus faecal immunochromatography testing in colorectal cancer screening. Cancer Causes Control. 2014;25:985–997.
6. Duarte RB, Bernardo WM, Sakai CM, et al. Computed tomography colonography versus colonoscopy for the diagnosis of colorectal cancer: a systematic review and meta-analysis. Ther Clin Risk Manag. 2018;14:349–360.

FIGURE 4. Examples of colonoscopy findings in the WBF with PB and control groups. PB indicates probiotics; WBF, wheat bran fiber.

TABLE 4. Outcomes of Colonoscopy in the WBF+PB and Control Groups

| Findings                  | WBF+PB Group (n = 20) | Control Group (n = 20) | P  |
|---------------------------|-----------------------|------------------------|----|
| Polyp                      | No (13 (65.0))        | 11 (55.0)              | 0.3406 |
| Location of polyps         | C (1 (4.0))           | 0 (0.0)                |    |
| A (11 (44.0))             | 3 (18.8)              |                        |    |
| T (7 (28.0))              | 3 (18.8)              |                        |    |
| D (2 (8.0))               | 2 (12.5)              |                        |    |
| S (0 (0.0))               | 5 (31.3)              |                        |    |
| R (4 (16.0))              | 3 (18.8)              |                        |    |
| Location of polyps [right side (C-T) or left side (D-R)] | |    |
| Right (19 (76.0))         | 6 (37.5)              | 0.0220                 |    |
| Left (6 (24.0))           | 10 (62.5)             |                        |    |
| No. polyps [mean (range)] | 1.25 ± 0.35 (0-6)     | 0.80 ± 0.24 (0-3)      | 0.2904 |
| Size of polyps [mean (range)] | 6.16 ± 0.80 (3-20)   | 5.56 ± 0.58 (3-10)    | 0.5897 |
| Diverticulum               | No (14 (70.0))        | 11 (55.0)              | 0.5145 |
| Yes (6 (30.0))            | 9 (45.0)              |                        |    |
| Colitis                   | No (18 (90.0))        | 17 (85.0)              | 1.0000 |
| Yes (2 (10.0))            | 3 (15.0)              |                        |    |
| Advanced cancer            | No (20 (100.0))       | 19 (95.0)              | 1.0000 |
| Yes (0 (0.0))             | 1 (5.0)               |                        |    |

Data are presented as the number (%) unless otherwise stated.
A indicates ascending colon; C, cecum; D, descending colon; PB, probiotics; R, rectum; S, sigmoid colon; T, transverse colon; WBF, wheat bran fiber.
7. Ishizuka A, Tomizuka K, Aoki R, et al. Effects of administration of *Bifidobacterium animalis* subsp. *lactis* GCL2505 on defecation frequency and bifidobacterial microbiota composition in humans. *J Biosci Bioeng*. 2012;113:587–591.

8. Takii H, Nishijima T, Takami K, et al. Effects of fermented milk containing *Bifidobacterium animalis* subsp. *lactis* GCL2505 on improvement of defecation, fecal properties, and intestinal microflora in healthy subjects with mild constipation. *Jpn Pharmacol Ther*. 2012;40:657–665.

9. Tanaka Y, Takami K, Nishijima T, et al. Short-and long-term dynamics in the intestinal microbiota following ingestion of *Bifidobacterium animalis* subsp. *lactis* GCL2505. *Biosci Microbiota Food Health*. 2015;34:77–85.

10. Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther*. 2016;44:693–703.

11. Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to simplify evaluation and management of constipated patients. *Dis Colon Rectum*. 1996;39:681–685.

12. Macrae FA, Kilias D, Selbie L, et al. Effect of cereal fibre source and processing on rectal epithelial cell proliferation. *Gut*. 1997;41:239–244.

13. Halphen M, Hershbach D, Gruss HJ, et al. Validation of the Harefield Cleansing Scale: a tool for the evaluation of bowel cleansing quality in both research and clinical practice. *Gastrointest Endosc*. 2013;78:121–131.

14. Waldmann E, Penz D, Majcher B, et al. Impact of high-volume, intermediate-volume and low-volume bowel preparation on colonoscopy quality and patient satisfaction: an observational study. *United European Gastroenterol J*. 2019;7:114–124.

15. Spiller GA, Story JA, Wong LG, et al. Effect of increasing levels of hard wheat fiber on fecal weight, minerals and steroids and gastro-intestinal transit time in healthy young women. *J Nutr*. 1986;116:778–785.

16. Slavin JL. Implementation of dietary modifications. *Am J Med*. 1999;106:46S–51S.

17. Huang YL, Tsai YH, Chow CJ. Water-insoluble fiber-rich fraction from pineapple peel improves intestinal function in hamsters: evidence from cecal and fecal indicators. *Nutr Res*. 2014;34:346–354.